A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

MacroGenics

Status and phase: Completed; Phase 1

Conditions: Hematologic Neoplasms; Small-cell Lung Cancer; TNBC - Triple-Negative Breast Cancer; Advanced Solid Tumors; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Non Small Cell Lung Cancer; Ovarian Cancer; Cervical Cancer; HER2-positive Advanced Solid Tumors

Treatments: Biological: tebotelimab 3 mg; Biological: margetuximab; Biological: tebotelimab 800 mg; Biological: tebotelimab 30 mg; Biological: tebotelimab 10 mg; Biological: tebotelimab 1200 mg; Biological: tebotelimab 400 mg; Biological: tebotelimab 1 mg; Biological: tebotelimab 300 mg; Biological: tebotelimab 120 mg; Biological: tebotelimab 600 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03219268

CP-MGD013-01

Details and patient eligibility

About

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Enrollment: 277 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven, locally advanced unresectable or metastatic solid tumors (or hematologic malignancies, Cohort Expansion only) for whom no approved therapy with demonstrated clinical benefit is available or standard treatment was declined.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Life expectancy ≥ 12 weeks
• Measurable disease
• Tissue specimen available for retrospective analysis of PD-1, PD-L1, LAG-3, and MHC-II expression
• Acceptable laboratory parameters

HER2+ Cohort:

• Locally advanced or metastatic HER2+ locally advanced or metastatic solid tumors, regardless of organ of origin.

i. The cancer must have progressed following standard therapy, or has progressed during or after HER2-directed therapy if approved and available for patients with HER2+ breast, gastric, or gastroesophageal junction cancer.

ii. History of HER2 positivity defined as 3+ by IHC or 2+ by Immunohistochemistry (IHC) in combination with in situ hybridization (ISH) positivity most recent tumor biopsy.

• All patients in the HER2+ cohort must be willing to provide consent for a baseline and on-treatment tumor biopsy during the screening period and within 14 days prior to Cycle 3 Day 1. Exceptions may be made based on a medical contraindication at the discretion of the Sponsor's Medical Monitor. This requirement will be discontinued after an adequate number of samples are collected, as determined by the Sponsor.

Exclusion criteria

• Symptomatic central nervous system (CNS) metastases or primary CNS lymphoma
• History of allogeneic bone marrow, stem-cell, or solid organ transplant
• History of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
• Treatment with any systemic chemotherapy within 3 weeks prior to the initiation of study drug; treatment with biologics or investigational therapy within the 4 weeks prior to the initiation of study drug.
• Major surgery within 4 weeks prior to the initiation of study drug.
• Prior treatment with combination of monoclonal antibodies against PD-1 and LAG-3 (Cohort Expansion only).
• Treatment with radiation therapy within 2 weeks prior to the initiation of study drug.
• Clinically significant cardiovascular disease.
• QTcF prolongation > 480 milliseconds
• HER2+ cohort: left ventricular ejection fraction less than 50%
• Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.
• Active pneumonitis or history of non-infectious pneumonitis.
• Clinically significant gastrointestinal disorders.
• Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
• Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
• Known history of hepatitis B (except in hepatocellular carcinoma) or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR)
• Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
• Dementia or altered mental status that would preclude understanding and rendering of informed consent
• Confirmed or presumed COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines/standards. Patients with a positive test result for SARS-CoV-2 infection, known asymptomatic infection, or presumed infection are excluded. Patients may be considered eligible after a resolved SARS-CoV-2 infection once he or she remains afebrile for at least 72 hours and after other SARS-CoV-2-related symptoms have fully recovered to baseline for a minimum of 72 hours.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

277 participants in 12 patient groups

Tebotelimab: 1 mg

Experimental group

Treatment:

Biological: tebotelimab 1 mg

Tebotelimab 3 mg

Experimental group

Treatment:

Biological: tebotelimab 3 mg

Tebotelimab: 10 mg

Experimental group

Treatment:

Biological: tebotelimab 10 mg

Tebotelimab: 30 mg

Experimental group

Treatment:

Biological: tebotelimab 30 mg

Tebotelimab: 120 mg

Experimental group

Treatment:

Biological: tebotelimab 120 mg

Tebotelimab: 400 mg

Experimental group

Treatment:

Biological: tebotelimab 400 mg

Tebotelimab: 600 mg

Experimental group

Treatment:

Biological: tebotelimab 600 mg

Tebotelimab: 800 mg

Experimental group

Treatment:

Biological: tebotelimab 800 mg

Tebotelimab: 1200 mg

Experimental group

Treatment:

Biological: tebotelimab 1200 mg

Combination cohort 1

Experimental group

Description:

Tebotelimab and margetuximab

Treatment:

Biological: tebotelimab 300 mg

Biological: margetuximab

Combination Cohort 2

Experimental group

Description:

Tebotelimab and margetuximab

Treatment:

Biological: tebotelimab 600 mg

Biological: margetuximab

Monotherapy Cohort Expansion

Experimental group

Description:

Monotherapy expansion at 600 mg

Treatment:

Biological: tebotelimab 600 mg